{"id":8976,"date":"2025-10-21T09:28:54","date_gmt":"2025-10-21T06:28:54","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8976"},"modified":"2025-10-21T09:28:54","modified_gmt":"2025-10-21T06:28:54","slug":"pci-tavr-combination-oct-2025","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/pci-tavr-combination-oct-2025\/","title":{"rendered":"PCI + TAVR Combination (Oct 2025)"},"content":{"rendered":"<div>PCI + TAVR Combination (Oct 2025)<\/div>\n<div><\/div>\n<div>ScienceDirect \u2014 October 10, 2025.<\/div>\n<div><\/div>\n<div><span> keynotes:<\/span><\/div>\n<div>\u00a0 \u00a0 \u00a0 1.<span> <\/span>Study (2019\u20132024, &gt;200 patients) compared simultaneous PCI\/TAVR vs. staged PCI then TAVR.<\/div>\n<div><span> 2. In-hospital outcomes: similar mortality (2% vs. 4%), no excess stroke, MI, or AKI.<\/span><\/div>\n<div><span> 3. 3-year results: combined PCI\/TAVR showed better survival (+68 days) and less bleeding.<\/span><\/div>\n<div><span> 4. Authors conclude the simultaneous approach is safe and may offer short- and long-term benefits<\/span><\/div>\n<div>5.\u00a0 Antithrombotic Therapy After Combined PCI + TAVR<\/div>\n<div><span> 1. Goal: Balance thrombosis prevention with bleeding risk after simultaneous PCI and TAVR.<\/span><\/div>\n<div><span> 2. Recommended Approach:<\/span><\/div>\n<div>* DAPT (Aspirin + Clopidogrel) for 1\u20136 months, then Aspirin alone long-term.<\/div>\n<div>* If oral anticoagulation (OAC) is needed (e.g., for AF), use OAC + Clopidogrel for 1\u20133 months, then OAC alone.<\/div>\n<div>* Triple therapy (OAC + DAPT) should be avoided or limited to \u22641 month in high ischemic risk.<\/div>\n<div><span> 3. TAVR Only: Single antiplatelet therapy (Aspirin) is usually sufficient unless another indication for OAC exis<\/span><\/div>\n<div><\/div>\n<div><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1553838925005135#t0010\">https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1553838925005135#t0010<\/a><\/div>\n<div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PCI + TAVR Combination (Oct 2025) ScienceDirect \u2014 October 10, 2025. keynotes: \u00a0 \u00a0 \u00a0 1. Study (2019\u20132024, &gt;200 patients) compared simultaneous PCI\/TAVR vs. staged PCI then TAVR. 2. In-hospital outcomes: similar mortality (2% vs. 4%), no excess stroke, MI, or AKI. 3. 3-year results: combined PCI\/TAVR showed better survival (+68 days) and less bleeding. [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8976","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8976","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8976"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8976\/revisions"}],"predecessor-version":[{"id":8977,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8976\/revisions\/8977"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8976"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8976"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8976"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}